What is US4020727A, and what does it cover for metformin hydrochloride?
US4020727A is a U.S. patent document titled around metformin hydrochloride, a biguanide antidiabetic compound used in type 2 diabetes. It is part of the early patent landscape for metformin rather than a later reformulation or new clinical-use patent. [1]
When was US4020727A filed, and when would it have expired (in practice)?
Patent term depends on filing date and the specific rules that applied at the time, but for early-generation patents like those in the metformin origin period, the practical result is that the original composition patent protections would have long since ended. For modern confirmation of a specific patent’s legal status and dates, a patent-status resource is needed rather than relying on the document number alone. [1]
How does this relate to current metformin products and generic availability?
Because metformin hydrochloride is an established generic drug in most markets, patents from the original era (including documents like US4020727A) do not block today’s generic metformin products. The current availability picture is instead driven by later patents (if any) for specific formulations, fixed-dose combinations, or extended-release versions. [1]
Is US4020727A still enforceable?
For historical metformin hydrochloride patents of this type, enforceability is generally not expected today due to patent-term time limits. To verify, you would check the patent’s maintenance status and any terminal disclaimers or relevant litigation—information not contained in the question alone. [1]
Where can I read the patent text and claims?
You can view the full patent record (including the title, assignee, and claims) via the patent document entry on DrugPatentWatch.com, which also links out to related patent/publication context. [1]
Sources
[1] https://www.drugpatentwatch.com/p/4020727-a